MARKETS
Analyst Actions

HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price Target

Sep 24, 2026 · 06:26 AM ET· updated 12h ago

HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $1201 price target.

Share
Why It Matters

An analyst thinks Praxis is a good company to own right now. They believe the stock could be worth around $120 per share in the future.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.